Atherosclerotic Cardiovascular Disease in Type 2 Diabetes : A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
Steen Carlsson, Katarina LU
; Faurby, Mads
; Nilsson, Kristoffer
and Wolden, Michael Lyng
(2023)
In Diabetes Therapy
14(8).
p.1357-1372
- Abstract
Introduction: Individuals with type 2 diabetes (T2D) are at high risk of experiencing atherosclerotic cardiovascular disease (ASCVD), which is associated with morbidity, mortality and healthcare resource utilisation. Clinical guidelines recommend the use of glucose-lowering medications with cardiovascular benefits in individuals with T2D and cardiovascular disease, but there is evidence that this is not reflected in clinical practice. We used linked national registry data from Sweden to compare outcomes in people with T2D and ASCVD against matched controls with T2D without ASCVD, over 5 years. Direct costs (inpatient, outpatient and selected drug costs), indirect costs resulting from work absence, early retirement, cardiovascular events... (More)
Introduction: Individuals with type 2 diabetes (T2D) are at high risk of experiencing atherosclerotic cardiovascular disease (ASCVD), which is associated with morbidity, mortality and healthcare resource utilisation. Clinical guidelines recommend the use of glucose-lowering medications with cardiovascular benefits in individuals with T2D and cardiovascular disease, but there is evidence that this is not reflected in clinical practice. We used linked national registry data from Sweden to compare outcomes in people with T2D and ASCVD against matched controls with T2D without ASCVD, over 5 years. Direct costs (inpatient, outpatient and selected drug costs), indirect costs resulting from work absence, early retirement, cardiovascular events and mortality were examined. Methods: Individuals with T2D who were at least 16 years old and were alive and resident in Sweden on 1 January 2012 were identified in an existing database. In four separate analyses, individuals with a record indicating ASCVD according to a broad definition, peripheral artery disease (PAD), stroke or myocardial infarction (MI) before 1 January 2012 were identified using diagnosis and/or procedure codes and propensity score matched 1:1 to controls with T2D and without ASCVD, using covariates for birth, sex and level of education in 2012. Follow-up continued until death, migration from Sweden or the end of the study period in 2016. Results: In total, 80,305 individuals with ASCVD, 15,397 individuals with PAD, 17,539 individuals with previous stroke and 25,729 individuals with previous MI were included. Total mean annual costs per person were €14,785 for PAD (2.7 × costs for controls), €11,397 for previous stroke (2.2 × controls), €10,730 for ASCVD (1.9 × controls) and €10,342 for previous MI (1.7 × controls). Indirect costs and costs of inpatient care were the major cost drivers. ASCVD, PAD, stroke and MI were all associated with an increased likelihood of early retirement, cardiovascular events and mortality. Conclusions: ASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.
(Less)
- author
- Steen Carlsson, Katarina
LU
; Faurby, Mads
; Nilsson, Kristoffer
and Wolden, Michael Lyng
- organization
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Atherosclerotic cardiovascular disease, Cardiovascular events, Healthcare costs, Indirect costs, Mortality, Myocardial infarction, Peripheral artery disease, Stroke, Type 2 diabetes
- in
- Diabetes Therapy
- volume
- 14
- issue
- 8
- pages
- 16 pages
- publisher
- Springer
- external identifiers
-
- pmid:37326822
- scopus:85161984713
- ISSN
- 1869-6953
- DOI
- 10.1007/s13300-023-01430-4
- language
- English
- LU publication?
- yes
- id
- 7ab8530a-ab0b-4b41-8782-012c21c602ed
- date added to LUP
- 2023-09-11 15:40:21
- date last changed
- 2024-04-20 03:04:26
@article{7ab8530a-ab0b-4b41-8782-012c21c602ed,
abstract = {{<p>Introduction: Individuals with type 2 diabetes (T2D) are at high risk of experiencing atherosclerotic cardiovascular disease (ASCVD), which is associated with morbidity, mortality and healthcare resource utilisation. Clinical guidelines recommend the use of glucose-lowering medications with cardiovascular benefits in individuals with T2D and cardiovascular disease, but there is evidence that this is not reflected in clinical practice. We used linked national registry data from Sweden to compare outcomes in people with T2D and ASCVD against matched controls with T2D without ASCVD, over 5 years. Direct costs (inpatient, outpatient and selected drug costs), indirect costs resulting from work absence, early retirement, cardiovascular events and mortality were examined. Methods: Individuals with T2D who were at least 16 years old and were alive and resident in Sweden on 1 January 2012 were identified in an existing database. In four separate analyses, individuals with a record indicating ASCVD according to a broad definition, peripheral artery disease (PAD), stroke or myocardial infarction (MI) before 1 January 2012 were identified using diagnosis and/or procedure codes and propensity score matched 1:1 to controls with T2D and without ASCVD, using covariates for birth, sex and level of education in 2012. Follow-up continued until death, migration from Sweden or the end of the study period in 2016. Results: In total, 80,305 individuals with ASCVD, 15,397 individuals with PAD, 17,539 individuals with previous stroke and 25,729 individuals with previous MI were included. Total mean annual costs per person were €14,785 for PAD (2.7 × costs for controls), €11,397 for previous stroke (2.2 × controls), €10,730 for ASCVD (1.9 × controls) and €10,342 for previous MI (1.7 × controls). Indirect costs and costs of inpatient care were the major cost drivers. ASCVD, PAD, stroke and MI were all associated with an increased likelihood of early retirement, cardiovascular events and mortality. Conclusions: ASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.</p>}},
author = {{Steen Carlsson, Katarina and Faurby, Mads and Nilsson, Kristoffer and Wolden, Michael Lyng}},
issn = {{1869-6953}},
keywords = {{Atherosclerotic cardiovascular disease; Cardiovascular events; Healthcare costs; Indirect costs; Mortality; Myocardial infarction; Peripheral artery disease; Stroke; Type 2 diabetes}},
language = {{eng}},
number = {{8}},
pages = {{1357--1372}},
publisher = {{Springer}},
series = {{Diabetes Therapy}},
title = {{Atherosclerotic Cardiovascular Disease in Type 2 Diabetes : A Retrospective, Observational Study of Economic and Clinical Burden in Sweden}},
url = {{http://dx.doi.org/10.1007/s13300-023-01430-4}},
doi = {{10.1007/s13300-023-01430-4}},
volume = {{14}},
year = {{2023}},
}